Innovations in Pharmacological Treatments for the Pre-Cataract Presbyopic Patient

Edward J. Holland, MD

Professor of Ophthalmology
University of Cincinnati
Director, Cornea Service
Cincinnati Eye Institute
Cincinnati, Ohio
 

Nicole Fram, MD

Managing Partner at Advanced Vision Care in Los Angeles, CA
Clinical Instructor of Ophthalmology
Stein Eye Institute
University of California,Los Angeles

Marjan Farid, MD

Director of Cornea, Cataract, and Refractive Surgery
Vice Chair of Ophthalmic Faculty
Clinical Professor of Ophthalmology
Gavin Herbert Eye Institute
University of California, Irvine

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Alcon Vision, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, BRIM biotech, Carl Zeiss Medtec, Claris Bio, Corneat, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Glaukos, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck, Novartis Pharmaceuticals, Ocular Therapeutix, Ocuphire, Omeros, Oyster Point Pharma, Precise Bio, Prometic Biotherapeutics, ReGentree, Retear, Senju, Shire, Sight Sciences, Slack, Tarsus RX, TearLab, Vomaris, and W.L. Gore and Associates. Speaker’s List: Alcon Vision, Novartis Pharmaceuticals, Omeros, Senju, and Shire. Other Financial/Material Support: Alcon Vision, Mati Therapeutics, Novartis Pharmaceuticals, Omeros, Senju, and Shire.

Nicole Fram, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, CorneaGen, Johnson & Johnson Vision, and Ocular Therapeutics. Grant/Research Support: Alcon Vision, and Allergan. Speaker’s List: Alcon Vision, BVI, CorneaGen, Dompé, MST, and Ocular Therapeutix. Stock/Shareholder: CorneaGen, and Ocular Science.

Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, BioTissue, Carl Zeiss Meditec, CorneaGen, Dompé, Eyepoint Pharmaceuticals, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, and Novartis.

The staff and planners from Evolve and The Fundingsland Group have no financial relationships with commercial interests.  Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.